Investor Alert

New York Markets Open in:

May 10, 2022, 7:50 a.m. EDT



You should read the following in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form 10-Q


We are a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. In December 2019, CAPLYTA (lumateperone) was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of schizophrenia in adults (42mg/day) and we initiated the commercial launch of CAPLYTA in late March 2020. In support of our commercialization efforts, we employ a national sales force. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). CAPLYTA is the only

Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder, or MDD. Patient enrollment in Study 501 and Study 502, our global Phase 3 clinical trials evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD is ongoing. We expect to file an sNDA with the FDA for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD in 2024. In the first quarter of 2020, as part of our lumateperone bipolar depression clinical program, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with bipolar I or bipolar II disorder. Following the positive results in our adjunctive study that was part of our bipolar depression clinical program, Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with bipolar I or bipolar II disorder and mixed features in patients with MDD. We expect to complete Study 403 in the second half of 2022 and following completion we intend to discuss the results with the FDA to determine whether Study 403, as amended, will provide supportive data for a potential future regulatory filing for this indication.

We have also initiated a Phase 3 study evaluating lumateperone for the prevention of relapse in patients with schizophrenia. The study is being conducted in five phases consisting of a screening phase, a 6-week,

Within the lumateperone portfolio, we are also developing a long-acting injectable, or LAI, formulation to provide more treatment options to patients suffering from mental illness. We have completed the preclinical development of an LAI formulation, and in December 2020, we initiated a Phase 1 single ascending dose study of lumateperone LAI, a formulation of lumateperone designed to be administered subcutaneously and to maintain therapeutic levels of lumateperone for at least one month. This study is evaluating the pharmacokinetics, safety and tolerability of lumateperone LAI in patients with stable symptoms of schizophrenia. We are now exploring alternate sites of injection with this formulation as well as progressing other formulations. This will assist us in evaluating dosing strategies and formulation for our efficacy studies. The goal of our program is to develop LAI formulations that are effective, safe and well-tolerated with treatment durations of one month and longer. Given the encouraging tolerability data to date with oral lumateperone, we believe that an LAI option, in particular, may lend itself to being an important formulation choice for certain patients.

Table of Contents

We are developing

        for the treatment of behavioral disturbances in patients with dementia, the
        treatment of dementia-related psychosis and for the treatment of certain
        depressive disorders in the elderly.
        is a deuterated form of lumateperone, a new molecular entity formulated as an
        oral disintegrating tablet for sublingual administration.
        is formulated as an oral solid dosage form that dissolves almost instantly when
        placed under the tongue, allowing for ease of use in the elderly and may be
        particularly beneficial for patients who have difficulty swallowing conventional
        tablets. Phase 1 single and multiple ascending dose studies in healthy
        volunteers and healthy elderly volunteers (> than 65 years of age) evaluated the
        safety, tolerability and pharmacokinetics of
        In these studies, there were no reported serious adverse events in either age
        group. In the elderly cohort, reported adverse events were infrequent with the
        most common adverse event being transient dry mouth (mild). Based on these
        results, we have initiated our program evaluating
        for the treatment of agitation in patients with probable Alzheimer's disease. We
        are in discussions with the FDA regarding the
        toxicological profile of
        The FDA has informed us that they do not believe the deuterated and undeuterated
        forms of lumateperone are identical. As a result, the
        data from lumateperone may not be broadly applied to
        and we may be required to conduct additional toxicology studies in
        species. This could delay the commencement of our clinical program. We expect to
        commence clinical conduct in this program in 2022. Additional studies in
        dementia-related psychosis and certain depressive disorders in the elderly are
        also planned for late 2022 or early 2023.

We have another major program that has yielded a portfolio of compounds that selectively inhibit the enzyme phosphodiesterase type 1, or PDE1. PDE1 enzymes are highly active in multiple disease states and our PDE1 inhibitors are designed to reestablish normal function in these disease states. Abnormal PDE1 activity is associated with cellular proliferation and activation of inflammatory cells. Our PDE1 inhibitors ameliorate both of these effects in animal models. We intend to pursue the development of our phosphodiesterase, or PDE, program, for the treatment of aberrant immune system activation in several CNS

We also have a development program with

        is a novel compound that uniquely combines activity as an antagonist at
        serotonin 5-HT2A receptors
        and a partial agonist at �-opioid receptors. These combined actions support the
        potential utility
        of ITI-333 in
        the treatment of opioid use disorder and associated comorbidities (e.g.,
        depression, anxiety, sleep disorders) without opioid-like safety and
        tolerability concerns. In December 2020, we initiated a Phase 1 single ascending
        dose study evaluating the safety, tolerability and pharmacokinetics of
        in healthy volunteers. This study was recently completed and
        achieved plasma exposures at or above those required for efficacy and was
        generally safe and well-tolerated. We have received a grant from the National
        Institute on Drug Abuse under the Helping to End Addiction Long-term Initiative,
        or NIH HEAL Initiative, that we expect will fund a significant portion of the
        early stage clinical development costs associated with this program.

We have assembled a management team with significant industry experience to lead the commercialization of our product and the discovery, development and potential commercialization of our product candidates. We complement our management team with a group of scientific and clinical advisors that includes recognized experts in the fields of schizophrenia, bipolar depression and other CNS disorders.

Table of Contents


In December 2019, a novel strain of

        surfaced in Wuhan, China. Since then,
        have spread to countries worldwide, including the United States. The
        pandemic continues to evolve, and to date has led to the implementation of
        various responses, including government-imposed quarantines, travel restrictions
        and other public health safety measures. As a result of the
        pandemic, or similar pandemics, we may experience disruptions that could
        severely impact our business, including our ability to successfully
        commercialize our only commercial product, CAPLYTA, in the United States, and
        these disruptions could negatively impact our sales of CAPLYTA. Depending on the
        severity of the pandemic, our commercial organization, sales force and medical
        organization may have significantly reduced personal interactions with
        physicians and customers and may need to conduct many promotional activities
        virtually, and we may elect to cease
        interactions with physicians and customers entirely for some period of time in
        the interest of employee and community safety. In addition, this could result in
        a decrease in the number of patient visits to healthcare providers. Business
        interruptions from the current or future pandemics may also adversely impact the
        third parties we rely on to sufficiently manufacture CAPLYTA and to produce our
        product candidates in quantities we require, which may impair the
        commercialization and our research and development activities.

We conduct clinical trials for our product candidates in many countries and regions, including the United States and Europe and may expand to other geographies. Timely enrollment of, completion of and reporting on our clinical trials is dependent upon these global clinical trial sites which are, or in the future may be, adversely affected by

        pandemic that have or may adversely affect the timing and conduct of our
        clinical trials and adversely impact our business generally, include but are not
        limited to delays or difficulties in clinical site initiation, patient
        enrollment, diversion of healthcare resources away from clinical trials to
        pandemic concerns, limitations on travel, regulatory delays and supply chain

In response to the

        pandemic, in March 2020, the FDA announced its intention to temporarily postpone
        most inspections of foreign manufacturing facilities and products, as well as
        routine surveillance inspections of domestic manufacturing facilities, and it
        also provided guidance regarding the conduct of clinical trials, which has been
        further updated several times since that time. In
        the FDA noted it was continuing to ensure timely reviews of applications for
        medical products during the
        pandemic in line with its user fee performance goals and conducting
        mission-critical domestic and foreign inspections to ensure compliance of
        manufacturing facilities with FDA quality standards. The FDA subsequently
        publicized its development and use of an internal rating system, called the
        Advisory Rating system, to assist in determining when and where it is safest to
        conduct such inspections based on data about the virus's trajectory in a given
        country, state and locality and the rules and guidelines that are put in place
        by foreign, state and local governments. As of October 2021, FDA is either
        continuing to, on a
        basis, conduct only "mission-critical" inspections, or, where possible to do so
        safely, resuming prioritized domestic inspections, which generally include
        inspections, or PAIs. Foreign PAIs that are not deemed mission-critical remain
        postponed, while those deemed mission-critical will be considered for inspection
        on a
        basis. FDA will use similar data to inform resumption of other prioritized
        operations abroad as it becomes feasible and advisable to do so.

During the global response to the

        pandemic, moreover, there have been strategic redeployments of government
        resources to priority projects, including FDA and EMA resources and staff, which
        could have an impact on the timeline for review and approval of new marketing
        applications. Over the course of the pandemic, FDA's new drug review programs
        continued to meet key performance goals related to working with applicants and
        approving NDAs and NDA supplements, although the agency has also stated that the
        uncertainty of the
        situation may make it difficult to sustain that level of performance
        indefinitely. The FDA may not be able to maintain its normal pace with respect
        to new drug applications and delays or setbacks are possible in the future. The
        FDA has told industry that it intends to be as transparent as possible about its
        workload and performance metrics as the situation evolves, and also that it
        intends to communicate proactively with applicants during the review cycle
        regarding the need for a
        inspection and whether such PAI is considered "mission-critical."

Should FDA determine that a PAI is necessary for approval of an NDA or NDA supplement and such an inspection cannot be completed during the review cycle due to restrictions on travel or other safety protocols, FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. Such decisions will be based on the totality of the information available to the FDA, including considerations of whether it can obtain existing inspection reports from trusted foreign regulatory partners through mutual recognition and confidentiality agreements and/or secure additional records from the applicant, the manufacturing facility, or other inspected entities. Accordingly, FDA has encouraged applicants to effectively communicate with all of their facilities and sites to ensure timely responses to any inquiries from FDA for information needed to support its assessment of pending drug applications. FDA has also stated that it is using all available tools and sources of information to support regulatory decisions on NDAs such as the historical compliance status of a manufacturing facility and other risk-benefit considerations pertaining to the proposed new drug product and its manufacturing process and facilities. In addition, whether or not FDA considers a facility inspection to be "mission-critical" involves several factors related to the public health benefits of the proposed new drug product,

Table of Contents

including but not limited to whether the candidate has been granted breakthrough therapy designation and whether the candidate is intended to treat or prevent a serious disease or medical condition for which there is no other appropriate substitute. Regulatory authorities outside the United States, including but not limited to the EMA, may adopt similar restrictions or other policy measures in response to

The COVID-19 pandemic

Results of Operations

The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.


Net revenues from product sales consist of sales of CAPLYTA, which was approved by the FDA for the treatment of schizophrenia in adults in December 2019 and for the treatment of bipolar depression in adults in December 2021. We initiated the commercial launch of CAPLYTA in late March 2020. During the three months ended March 31, 2022 and 2021, net sales increased from approximately $15.6 million for the three-month period ended March 31, 2021 to approximately $34.8 million for the three-month period ended March 31, 2022. In addition, we had approximately $0.2 million of grant revenues for the three-month period ended March 31, 2022, compared to approximately $0.3 million of grant revenues for the three-month period ended March 31, 2021. We have received and may continue to receive grants from U.S. government agencies and foundations.


The process of researching, developing and commercializing drugs for human use is lengthy, unpredictable and subject to many risks. We are unable, with certainty, to estimate either the costs or the timelines in which those costs will be incurred. The costs associated with the commercialization of CAPLYTA are substantial and will be incurred prior to our generating sufficient revenue to offset these costs. Costs for the clinical development of lumateperone-related projects, including for the treatment of MDD, consumes and, together with our other anticipated clinical development programs, will continue to consume a large portion of our current, as well as projected, resources. We intend to pursue other disease indications that lumateperone may address, but there are significant costs associated with pursuing FDA approval for those indications, which would include the cost of additional clinical trials.

Our PDE,

        development programs are currently in clinical stage development. Our other
        programs are still in the preclinical stages and will require extensive funding
        not only to complete preclinical testing, but also to commence and complete
        clinical trials. Expenditures that we incur on these programs will be subject to
        availability of funding in addition to the funding required for the advancement
        of lumateperone. Any failure or delay in the advancement of lumateperone could
        require us to
        resources from our other programs to the advancement of lumateperone, which
        could have a material adverse impact on the advancement of these other programs
        and on our results of operations.

Our operating expenses are comprised of (i) costs of product sales;

Costs of product sales are comprised of:

direct costs of formulating, manufacturing and packaging drug product;

overhead costs consisting of labor, customs, share-based compensation, shipping, outside inventory management and other miscellaneous operating costs; and

royalty payments on product sales.

Research and development costs are comprised of:

internal recurring costs, such as costs relating to labor and fringe benefits, materials, supplies, facilities and maintenance; and

fees paid to external parties who provide us with contract services, such as pre-clinical testing, manufacturing and related testing, clinical trial activities and license milestone payments.

Table of Contents

Selling expenses are incurred in three major categories:

salaries and related benefit costs of a dedicated sales force;

sales operation costs; and

marketing, promotional and advertising expenses.

General and administrative expenses are incurred in three major categories:

salaries and related benefit costs;

patent, legal, and professional costs; and

office and facilities overhead.

Product sold through March 31, 2022 consisted of drug product that was previously charged to research and development expense prior to FDA approval of CAPLYTA and other direct, indirect, and overhead costs required to make final product for sale. Because the Company's policy does not allow for the capitalization of

We expect to continue to have this favorable impact on cost of product sales and related product gross margins until our sales of CAPLYTA include drug product that is manufactured entirely after the FDA approval. We are currently unable to estimate how long it will be until we begin selling product entirely manufactured post FDA approval.

We expect that research and development expenses will increase as we proceed with our clinical trials, including increased manufacturing of drug product for clinical trials

The following table sets forth our revenues, operating expenses, interest income and income tax expense for the three-month periods ended March 31, 2022 and 2021 (in thousands):

                                                For the Three Months
                                                   Ended March 31,
                                                 2022           2021
        Product sales, net                    $   34,755      $  15,579
        Grant revenue                                241            299
        Total revenues, net                       34,996         15,878
        Cost of product sales                      3,155          1,455
        Research and development                  29,043         15,058
        Selling, general and administrative       75,460         52,584
        Total costs and expenses                 107,658         69,097
        Loss from operations                     (72,662 )      (53,219 )
        Interest income                              548            484
        Income tax expense                             ( )
                                                       5             (5 )
        Net loss                              $  (72,119 )    $ (52,740 )

. . .

May 10, 2022


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(c) 1995-2022 Cybernet Data Systems, Inc. All Rights Reserved

Link to MarketWatch's Slice.